Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT01613040
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 86
- Registration Number
- NCT01606436
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
CAEB071 Thorough QTc Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT01594255
- Locations
- 🇺🇸
Novartis Investigational Site, Austin, Texas, United States
Essentiality of INH in TB Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2018-04-06
- Target Recruit Count
- 69
- Registration Number
- NCT01589497
- Locations
- 🇿🇦
TASK Applied Science CRS (31718), Bellville, South Africa
🇿🇦University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa
Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT01565720
- Locations
- 🇺🇸
Parexel, Glendale, California, United States
Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 60
- Registration Number
- NCT01552928
- Locations
- 🇫🇷
Biotrial, Rueil-Malmaison, France
A Study of LY2484595 on the Electrical Activity of the Heart
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01537887
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY3009104 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT01536951
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
- Conditions
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 64
- Registration Number
- NCT01532115
- Locations
- 🇫🇷
Biotrial, 7-9 rue Jean-Louis Bertrand, Rennes, France
QTc Study GSK573719+GW642444
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT01521377
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.